Yissum - Research Development Company of the Hebrew University

"DIBAIT": a Novel Small Peptide For Type 2 Diabetes Treatment

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Di-Bait
Project ID : 7-2015-3167

Description of the technology

Our Innovation

Based on a provocative working hypothesis, we most probably identified the molecular origin of insulin resistance (IR). Systemic IR is induced via post-translational modification (PTM) of liver key regulatory proteins. We have discovered that hepatic futile utilization of the PTM-inducing residue, resulted in the abrogation of IR and correction of the glycemic-state, in type-2-diabetes (T2D) mouse model. We further found a way to achieve this glycemic control via the utilization of novel small molecules that operate through well-defined MoA. These novel small molecules are orally bioavailable and has nice safety profile.

Application

  • Providing a cure to T2D, as opposed to symptomatic treatment, by nullifying the vicious circle that starts with peripheral IR, as a result of fatty liver, and ends up as full-blown type-2-diabetes (T2D).

Pre-Clinical Results

  • Significant, persistent reduction in blood glucose level demonstrated in T2D animal model (db/db mice), following once a day injection of the peptide, observed already after 1 day.
  • Significant, persistent reduction in blood glucose level demonstrated in T2D animal model, following administration of DiBait therapy, observed already after 1 day.
  • This reduction in blood glucose occurs in diabetic but not in normal mice.
  • Significant reduction in plasma triglycerides in treated T2D mice with no effect on terminal plasma insulin or glucagon.

Opportunity

We are finishing now the process of drug-candidate selection and be ready in a few months to move to drug-development phase. A collaboration with major Pharma Company can help accelerating this process in terms of CMC, covering regulatory aspect etc. in order to bring an effective therapy to hundreds of millions of T2D patients around the world

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Shmuel Ben-Sasson
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Yuval Dor
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • metabolic

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.